跳至主要内容
临床试验/IRCT20210413050958N2
IRCT20210413050958N2尚未招募3 期

The effects of curcumin on the prevention of contrast induced nephropathy: A randomized double blind clinical trial

Mashhad University of Medical Sciences0 个研究点目标入组 227 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
入组人数
227

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • All subjects who receive IV. contrast agent (except renal artery angiography candidates)

排除标准

  • Hepatic failure (Child-Pugh Score B or C)
  • Biliary obstruction
  • End-stage renal insufficiency (eGFR less than 15 mL/min)
  • Acute renal insufficiency (BUN/Creatinine more than 20)
  • A history of reaction to contrast media
  • Taking potentially nephrotoxic medicines (48 h before and 24 h after the procedure)
  • Pulmonary oedema
  • Gastrointestinal disorders (such as diarrhea, vomiting, dehydration, bleeding, malabsorption, indigestion, etc.)
  • Multiple myeloma
  • Exposure to contrast media within 7 days before the procedure
  • Taking N-acetyl cysteine, teofiline, dopamine, fenoldopam, manitol, and NaHCO3 within 48 h before coronary angiography.

研究者

相似试验